Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hatch/Lieberman “BioShield II” Sets 180-Day Window For “Wild Card” Patents

Executive Summary

Manufacturers who enter into biodefense contracts must notify the government within 180 days which patent would be covered by a potential "wild card" extension under the final version of "BioShield II" legislation from Sens. Orrin Hatch (R-Utah), Joe Lieberman (D-Conn.) and Sam Brownback (R-Kan.)

You may also be interested in...



Capitol Hill News In Brief

FDA budget in limbo: The 109th congress failed to pass FY 2007 appropriations for FDA, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen in the Senate and House - Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wis.) - plan to scrap the current Republican-designed appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008. FDA said "a full-year continuing resolution presents difficult challenges" and added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...

Capitol Hill News In Brief

FDA budget in limbo: The 109th congress failed to pass FY 2007 appropriations for FDA, instead settling on a continuing resolution that expires Feb. 15. Incoming Democratic Appropriations Committee Chairmen in the Senate and House - Sen. Robert Byrd (W.Va.) and Rep. Dave Obey (Wis.) - plan to scrap the current Republican-designed appropriations bills in favor of a year-long continuing resolution. The move would effectively freeze the agency's spending at FY 2006 levels until FY 2008. FDA said "a full-year continuing resolution presents difficult challenges" and added that between now and Feb. 15, it "will be working with the administration to analyze the impacts of a continuing resolution"...

Priority Review Voucher Proposal To Be Considered By FDA

Potential "blockbuster" drugs could receive faster FDA review under a proposed system to encourage development of treatments for neglected diseases

Related Content

Topics

UsernamePublicRestriction

Register

PS045780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel